Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis
Introduction Phase I/II clinical trials suggested that the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway-targeted agents were active in suppression of gastric cancer (GC). Randomised controlled trials (RCTs) were undertaken assessing whether the addition of anti-HGF/...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e049575.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846129224109260800 |
|---|---|
| author | Chunyu Liu Bo Zhang Zhiyuan Jiang Zhaolun Cai Yuan Yin Chaoyong Shen Qin Ma Xiaonan Yin Chen Chang Zhou Zhao Mingchun Mu |
| author_facet | Chunyu Liu Bo Zhang Zhiyuan Jiang Zhaolun Cai Yuan Yin Chaoyong Shen Qin Ma Xiaonan Yin Chen Chang Zhou Zhao Mingchun Mu |
| author_sort | Chunyu Liu |
| collection | DOAJ |
| description | Introduction Phase I/II clinical trials suggested that the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway-targeted agents were active in suppression of gastric cancer (GC). Randomised controlled trials (RCTs) were undertaken assessing whether the addition of anti-HGF/MET agent (rilotumumab or onartuzumab) to chemotherapy improves survival outcomes of advanced GC, but conflict conclusions were reached. Therefore, we plan to perform this systematic review and meta-analysis to synthesise evidence concerning efficacy and safety of anti-HGF/MET agents combined with chemotherapy as the first-line treatment to advanced GC.Methods and analysis Systematic searches of the PubMed, Embase and the Cochrane Central Register of Controlled Trials will be performed with no language restriction from inception to 31 January 2022 to identify RCTs exploring the comparative efficacy and safety of anti-HGF/MET agents plus chemotherapy as first-line treatment in advanced GC. The primary outcome will be the time-to-event progression-free survival and overall survival, and the secondary outcomes will be disease control rate, overall adverse events rate and grade 3–5 adverse events rate. Statistical heterogeneity will be assessed by visual inspection of forest plots and measured using the I2 statistics. A fixed-effect model will be used when heterogeneity is low otherwise, a random-effect model will be chosen. Publication bias will be assessed by funnel plots; subgroup analysis and sensitivity analysis will be performed in the right context. For each outcome, we will perform data synthesis using Rev Man V.5.3 software, and compile ‘summary of findings’ tables using GRADEpro software.Ethics and dissemination There is no requirement for ethics approval because no individual data will be collected in this research. It is anticipated that the dissemination of results will take place at conferences and through publication in a peer-review journal, any adjustments from the protocol will be clearly documented and explained in its final report.PROSPERO registration number CRD42020177404. |
| format | Article |
| id | doaj-art-17bcb21d78c04c3daecbf3090676f60b |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-17bcb21d78c04c3daecbf3090676f60b2024-12-10T07:15:09ZengBMJ Publishing GroupBMJ Open2044-60552021-12-01111210.1136/bmjopen-2021-049575Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysisChunyu Liu0Bo Zhang1Zhiyuan Jiang2Zhaolun Cai3Yuan Yin4Chaoyong Shen5Qin Ma6Xiaonan Yin7Chen Chang8Zhou Zhao9Mingchun Mu101 Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USASanya People`s Hospital/ West China (Sanya) hospital, Sanya, ChinaDepartment of Gastrointestinal Surgery, Sichuan University West China Hospital, Chengdu, China1 Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People`s Republic of ChinaDepartment of Gastrointestinal Surgery, Sichuan University West China Hospital, Chengdu, China1 Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People`s Republic of ChinaDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA1 Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People`s Republic of ChinaDepartment of Abdominal Oncology, Cancer Center, Sichuan University West China Hospital, Chengdu, ChinaDepartment of Gastrointestinal Surgery, Sichuan University West China Hospital, Chengdu, ChinaDepartment of Gastrointestinal Surgery, Sichuan University West China Hospital, Chengdu, ChinaIntroduction Phase I/II clinical trials suggested that the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway-targeted agents were active in suppression of gastric cancer (GC). Randomised controlled trials (RCTs) were undertaken assessing whether the addition of anti-HGF/MET agent (rilotumumab or onartuzumab) to chemotherapy improves survival outcomes of advanced GC, but conflict conclusions were reached. Therefore, we plan to perform this systematic review and meta-analysis to synthesise evidence concerning efficacy and safety of anti-HGF/MET agents combined with chemotherapy as the first-line treatment to advanced GC.Methods and analysis Systematic searches of the PubMed, Embase and the Cochrane Central Register of Controlled Trials will be performed with no language restriction from inception to 31 January 2022 to identify RCTs exploring the comparative efficacy and safety of anti-HGF/MET agents plus chemotherapy as first-line treatment in advanced GC. The primary outcome will be the time-to-event progression-free survival and overall survival, and the secondary outcomes will be disease control rate, overall adverse events rate and grade 3–5 adverse events rate. Statistical heterogeneity will be assessed by visual inspection of forest plots and measured using the I2 statistics. A fixed-effect model will be used when heterogeneity is low otherwise, a random-effect model will be chosen. Publication bias will be assessed by funnel plots; subgroup analysis and sensitivity analysis will be performed in the right context. For each outcome, we will perform data synthesis using Rev Man V.5.3 software, and compile ‘summary of findings’ tables using GRADEpro software.Ethics and dissemination There is no requirement for ethics approval because no individual data will be collected in this research. It is anticipated that the dissemination of results will take place at conferences and through publication in a peer-review journal, any adjustments from the protocol will be clearly documented and explained in its final report.PROSPERO registration number CRD42020177404.https://bmjopen.bmj.com/content/11/12/e049575.full |
| spellingShingle | Chunyu Liu Bo Zhang Zhiyuan Jiang Zhaolun Cai Yuan Yin Chaoyong Shen Qin Ma Xiaonan Yin Chen Chang Zhou Zhao Mingchun Mu Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis BMJ Open |
| title | Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis |
| title_full | Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis |
| title_fullStr | Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis |
| title_full_unstemmed | Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis |
| title_short | Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis |
| title_sort | comparative efficacy and safety of anti hgf met pathway agents plus chemotherapy versus chemotherapy alone as first line treatment in advanced gastric cancer a protocol for a systematic review and meta analysis |
| url | https://bmjopen.bmj.com/content/11/12/e049575.full |
| work_keys_str_mv | AT chunyuliu comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT bozhang comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT zhiyuanjiang comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT zhaoluncai comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT yuanyin comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT chaoyongshen comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT qinma comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT xiaonanyin comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT chenchang comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT zhouzhao comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis AT mingchunmu comparativeefficacyandsafetyofantihgfmetpathwayagentspluschemotherapyversuschemotherapyaloneasfirstlinetreatmentinadvancedgastriccanceraprotocolforasystematicreviewandmetaanalysis |